On August 8, 2022 Helsinn Group ("Helsinn"), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, reported its participation in the upcoming IASLC 2022 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria (Press release, Helsinn, AUG 8, 2022, View Source [SID1234619490]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the conference, new preclinical data for the investigational product vepafestinib (TAS0953/HM06), a selective RET inhibitor that has shown a distinct binding mode1 to RET and a high brain barrier permeability2, will be presented on August 9, 2022, 12:12 – 12:17 CEST.
Details of the abstract are below:
Title: TA0953/HM06, a novel RET-specific inhibitor effective in extracranial and CNS disease models of NSCLC with RET fusions
Author: Igor Odintsov, MD
Session: MA13 – Update on ROS1 Inhibitors and New Pathways
Abstract ID: MA13.05
This Helsinn-sponsored study, which was conducted by Dr. Odintsov and colleagues in the Marc Ladanyi Lab at Memorial Sloan Kettering Cancer Center, explored the effect of vepafestinib (TAS0953/HM06), relative to other RET multi-kinase and selective inhibitors, on growth inhibition using in vitro and in vivo NSCLC extracranial and CNS disease models.
Dr. Sergio Cantoreggi, Helsinn Group Chief Scientific Officer and Head of R&D commented: "We are excited to be presenting further preclinical data on vepafestinib at the IASLC 2022 World Conference on Lung Cancer. RET alterations are a key driver in several types of cancer. The data presented on our investigational asset vepafestinib highlight Helsinn’s strong focus on targeted therapies for rare cancers and demonstrate the deployment of our fully integrated targeted therapy (FITT) strategy."
Dr. Igor Odintsov, MD, commented: "Cancers with RET alterations have a high incidence of brain metastasis at advance stage of the disease (for example, 25% of lung adenocarcinoma patients with stage IV disease had brain metastasis)3. Developing therapies for these patients to minimize CNS progression is critically important. These preclinical results support the continued investigation and development of vepafestinib in this disease space."